I. Dogan Et Al. , "Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib," TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, pp.413-418, 2022
Dogan, I. Et Al. 2022. Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib. TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37 , 413-418.
Dogan, I., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., ... Aydine, A.(2022). Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib. TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, 413-418.
Dogan, İzzet Et Al. "Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib," TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, 413-418, 2022
Dogan, İzzet Et Al. "Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib." TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, pp.413-418, 2022
Dogan, I. Et Al. (2022) . "Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib." TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , vol.37, pp.413-418.
@article{article, author={İzzet DOĞAN Et Al. }, title={Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib}, journal={TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY}, year=2022, pages={413-418} }